![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]()
Washington (UPI) Nov 22, 2010 The second clinical trial using human embryonic stem cells has been approved by the U.S. Food and Drug Administration, the company conducting the trial said. Biotech company Advanced Cell Technology of Marlborough, Mass., said Monday it has received approval for testing retinal cells in patients with Stargardt's macular dystrophy, a rare disease that causes progressive vision loss in children, AAAS ScienceMag.org reported. The company says it plans to treat 12 patients with advanced cases of the disease with up to 200,000 retinal pigment epithelium cells derived from human embryo stem cells transplanted directly into the eye, Robert Lanza, ACT's chief scientific officer, says. ACT, which applied for permission for its trial a year ago, is the second company to receive FDA approval for a human embryo stem cell trial. In October, Geron Corp. and the University of California, Irvine, began the first clinical trial involving embryo stem cells to treat spinal cord injury patients.
Share This Article With Planet Earth
Related Links The Clone Age - Cloning, Stem Cells, Space Medicine
![]() ![]() Houston TX (SPX) Nov 15, 2010 Gadonanotubes (GNTs) developed at Rice University are beginning to show positive results in a study funded by a federal stimulus grant through the National Institutes of Health (NIH) last year. The study has determined GNTs are effective in helping doctors track stems cells through the body by making them 40 times better than standard contrast agents used in magnetic resonance imaging. Con ... read more |
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2010 - SpaceDaily. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement,agreement or approval of any opinions, statements or information provided by SpaceDaily on any Web page published or hosted by SpaceDaily. Privacy Statement |